Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 8:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 414 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bleeding Complications Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy

NCT02472184
View directory record Official record
Conditions
Uterine Fibroids, Vaginal Bleeding
Interventions
Office hysteroscopy, Endometrial biopsy
Procedure
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 28, 2026, 8:30 PM EDT
Completed Phase 3 Interventional

Prevention of Esophageal Varices by Beta-Adrenergic Blockers

NCT00006398
View directory record Official record
Conditions
Esophageal and Gastric Varices, Liver Cirrhosis, Portal Hypertension
Interventions
Timolol Maleate, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
3
States / cities
New Haven, Connecticut • West Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 28, 2026, 8:30 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Effect of Early Administration of TXA in Adult Hip Fractures

NCT05047133
View directory record Official record
Conditions
Postoperative Blood Loss
Interventions
Tranexamic acid
Drug
Lead sponsor
Ascension Health
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Grand Blanc, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 28, 2026, 8:30 PM EDT
Completed Not applicable Interventional

Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)

NCT06634719
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Juveena Hydrogel System
Device
Lead sponsor
Rejoni Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Little Rock, Arkansas • West Orange, New Jersey • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 28, 2026, 8:30 PM EDT
Completed Phase 4 Interventional Results available

Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia

NCT01165307
View directory record Official record
Conditions
Menorrhagia
Interventions
Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation
Drug · Device
Lead sponsor
Abimbola Famuyide
Other
Eligibility
30 Years to 55 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 28, 2026, 8:30 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Suction Enabled Retraction Device

NCT03160170
View directory record Official record
Conditions
Surgical Blood Loss, Spinal Surgery
Interventions
SISTER device
Device
Lead sponsor
University of Miami
Other
Eligibility
22 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 28, 2026, 8:30 PM EDT
Terminated No phase listed Observational

Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer

NCT01563796
View directory record Official record
Conditions
Hematuria, Dysuria, Bladder Cancer
Interventions
Not listed
Lead sponsor
Medical Diagnostic Laboratories, LLC
Industry
Eligibility
25 Years and older
Enrollment
1,115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 28, 2026, 8:30 PM EDT
Active, not recruiting Not applicable Interventional

Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage

NCT06655207
View directory record Official record
Conditions
Post Partum Haemorrhage, Maternal Care Patterns, High Risk Pregnancy
Interventions
Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding
Device
Lead sponsor
Baymatob Operations Pty Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Denver, Colorado • Baton Rouge, Louisiana • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 28, 2026, 8:30 PM EDT
Terminated Phase 3 Interventional Results available

Adjunctive Application of BioFoam Surgical Matrix in Liver Surgery

NCT01458561
View directory record Official record
Conditions
Intraoperative Bleeding
Interventions
BioFoam Surgical Matrix, Gelfoam Plus
Device
Lead sponsor
CryoLife, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Palo Alto, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 28, 2026, 8:30 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery

NCT03856164
View directory record Official record
Conditions
Post Partum Hemorrhage, Fibrinolysis; Hemorrhage, Blood Loss
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 28, 2026, 8:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Postpartum Oxytocin Administration in the Era of Delayed Cord Clamping

NCT04632264
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Initiation of standard postpartum oxytocin immediately following fetal shoulder delivery, Initiation of standard postpartum oxytocin immediately following placenta delivery, Saline Placebo
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 28, 2026, 8:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Alternate Day Versus Daily Oral Iron Therapy in Adolescents

NCT05007899
View directory record Official record
Conditions
Iron Deficiency Anemia, Heavy Menstrual Bleeding, Abnormal Uterine Bleeding
Interventions
Ferrous sulfate
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
9 Years to 22 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 28, 2026, 8:30 PM EDT
Completed Not applicable Interventional

Decisionmaking for Abnormal Uterine Bleeding (AUB)

NCT01721304
View directory record Official record
Conditions
Abnormal Uterine Bleeding
Interventions
Adaptive Conjoint Analysis
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Indianapolis, Indiana • Southern Pines, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 28, 2026, 8:30 PM EDT
Completed Phase 1 Interventional

Vaginal Bromocriptine for Treatment of Adenomyosis

NCT01821001
View directory record Official record
Conditions
Adenomyosis
Interventions
Vaginal Bromocriptine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 28, 2026, 8:30 PM EDT
Completed Phase 3 Interventional Results available

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03751124
View directory record Official record
Conditions
Uterine Leiomyoma, Uterine Fibroids
Interventions
Relugolix, Estradiol/norethindrone acetate, Placebo for relugolix, Placebo for E2/NETA
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
72
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 28, 2026, 8:30 PM EDT
Withdrawn Not applicable Interventional

Fixed Low-dose Heparin Versus Standard Adjusted-dose Heparin Infusion in Adults Receiving Venovenous ECMO With a Heparin Bonded Circuit.

NCT02966080
View directory record Official record
Conditions
Acute Respiratory Failure, Extracorporeal Membrane Oxygenation Complication, Bleeding
Interventions
HEP-IV
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 28, 2026, 8:30 PM EDT
Completed Not applicable Interventional

Intraventricular Hemorrhage and Post Hemorrhagic Ventricular Dilation: Natural Course, Treatment, and Outcome

NCT00957840
View directory record Official record
Conditions
Intraventricular Hemorrhage, Premature Infants
Interventions
NIRS, aEEG, and CSF concentration of biomarkers
Procedure
Lead sponsor
University of Utah
Other
Eligibility
Up to 1 Year
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 28, 2026, 8:30 PM EDT
Withdrawn Phase 4 Interventional

Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis

NCT03325868
View directory record Official record
Conditions
Adenomyosis, Heavy Uterine Bleeding, Dysmenorrhea
Interventions
Ulipristal Acetate
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 51 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 28, 2026, 8:30 PM EDT
Recruiting Not applicable Interventional

Delivering Transcutaneous Auricular Neurostimulation to Reduce Blood Loss During Dialysis AV Graft Placement Procedures

NCT06647017
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Volta tAN System, SHAM Volta tAN System
Device
Lead sponsor
University Surgical Vascular
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Watkinsville, Georgia
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 28, 2026, 8:30 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study

NCT01968135
View directory record Official record
Conditions
Uterine Hemorrhage, Contraception
Interventions
Combined Oral Contraceptive Pill, Placebo Sugar Pill
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Oct 28, 2026, 8:30 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Oxytocin Receptor Expression in Pregnancy

NCT03907735
View directory record Official record
Conditions
Post-Abortion, Hemorrhage, Obstetric
Interventions
Myometrial tissue sample collection
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 28, 2026, 8:30 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections

NCT03303235
View directory record Official record
Conditions
Uterine Atony, Uterine Tone Disorders, Postpartum Hemorrhage
Interventions
Methylergonovine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 28, 2026, 8:30 PM EDT
Terminated No phase listed Observational Results available

Bypass vs. Ecmo in Lung Transplantation (BELT)

NCT03021538
View directory record Official record
Conditions
Lung Transplant; Complications
Interventions
Extracorporeal Membrane Oxygenation, Cardiopulmonary Bypass
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 28, 2026, 8:30 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas

NCT02147158
View directory record Official record
Conditions
Leiomyoma, Uterine Hemorrhage
Interventions
Ulipristal acetate (UPA), Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
61
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 28, 2026, 8:30 PM EDT